Xencor Inc
$ 12.09
2.20%
11 Jun - close price
- Market Cap 896,372,000 USD
- Current Price $ 12.09
- High / Low $ 12.27 / 11.56
- Stock P/E N/A
- Book Value 8.84
- EPS -2.29
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.30 %
- 52 Week High 18.69
- 52 Week Low 6.92
About
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Analyst Target Price
$28.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-27 | 2024-11-06 | 2024-08-05 | 2024-05-09 | 2024-02-27 | 2023-11-07 | 2023-08-03 |
| Reported EPS | -1.71 | -0.09 | -0.08 | -0.41 | -0.66 | -0.62 | -0.71 | -1.07 | -1.11 | -0.31 | -0.4 | -0.37 |
| Estimated EPS | -0.75 | -0.6037 | -0.7 | -0.68 | -0.58 | -0.7862 | -1.02 | -0.79 | -0.77 | -0.09 | -0.71 | -0.81 |
| Surprise | -0.96 | 0.5137 | 0.62 | 0.27 | -0.08 | 0.1662 | 0.31 | -0.28 | -0.34 | -0.22 | 0.31 | 0.44 |
| Surprise Percentage | -128% | 85.0919% | 88.5714% | 39.7059% | -13.7931% | 21.1397% | 30.3922% | -35.443% | -44.1558% | -244.4444% | 43.662% | 54.321% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.83 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XNCR
2026-06-07 19:09:25
This article analyzes Xencor Inc. (NASDAQ: XNCR) with a neutral near and mid-term outlook, but a potential long-term positive bias. It highlights a mid-channel oscillation pattern and offers three AI-generated trading strategies tailored for different risk profiles: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy. The analysis also provides multi-timeframe signal analysis, including support and resistance levels, for optimal positioning and risk management.
2026-06-01 06:39:19
Xencor Inc.'s shares are under scrutiny following partner Incyte's announcement that Monjuvi, an immunotherapy utilizing Xencor's technology, could become a first-line lymphoma treatment. This update provides a fresh fundamental backdrop for investors, occurring as the company also reported a significant Q1 2026 loss, with EPS of USD -1.71 against a consensus of USD -0.75. The company's business model relies on licensing engineered antibodies and cytokine therapies, making clinical and partnering milestones crucial for its investment phase.
2026-05-31 06:39:19
The article provides a technical analysis and stock price forecast for Xencor Inc (XNCR), indicating an overall "Strong Sell" consensus based on various technical indicators and moving averages. Key metrics like MACD and several moving averages suggest a bearish outlook, though some short-term moving averages show a "Buy" signal. The analysis also details support and resistance levels, and momentum indicators like RSI and Stochastic Oscillator.
2026-05-29 06:10:10
Xencor Inc. shares on Nasdaq are trading near their recent lows as investors weigh the company's antibody engineering pipeline and balance sheet against broader biotech market sentiment. The stock's valuation is sensitive to trial milestones, licensing deals, and funding, reflecting the inherent risks and opportunities of a clinical-stage biopharmaceutical company. Market analysts currently hold a "Hold" rating, indicating a balance between potential catalysts and development uncertainties.
2026-05-27 18:22:00
The article analyzes Xencor Inc. (NASDAQ: XNCR) using AI models, identifying a mid-channel oscillation pattern with an exceptional 101.0:1 risk-reward setup targeting a 27.5% gain. It provides three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods, alongside multi-timeframe signal analysis.
2026-05-25 09:40:01
Jefferies Financial Group Inc. significantly increased its stake in Xencor, Inc. by purchasing 620,440 shares in the fourth quarter, bringing its total holdings to 720,440 shares valued at approximately $11.0 million. This move comes amid mixed analyst sentiment, with the stock holding an average "Hold" rating and a consensus target price of $24.50. Meanwhile, insiders have been selling shares, with total insider sales reaching 44,020 shares over the last 90 days.
